egolinews.com

Arturus Capital Limited ( AKW “the Company”) is pleased to advise that it has reached agreement with Golden Gate Petroleum Ltd, (“GGP”) to sell 100% of its working interests in Caledonian Assets.

The consideration is US$8,000,000 by way of shares and cash and subject to shareholder and regulatory approvals. The Directors of AKW intend, subject to the necessary approvals, to issue the GGP shares issued as part consideration for this transaction in specie to its shareholders, Caledonian Assets On 24 March 2010 Arturus Energy LLC entered into an agreement to lease 8800 acres in the prolific Permian Basin (TEXAS). The leases are located in the Permian Basin in the Reagan and Irion Counties in Texas.

The Permian Basin is one of the most prolific producing oil and gas regions in the United States. It underlies an area of Southeastern New Mexico and West Texas approximately 250 miles wide and 300 miles long. Consideration AKW will receive an initial refundable deposit of US$500,000 by no later than 2 August and further US$2,000,000 cash within the later of 3 months. AKW will also receive 146,000,000 shares in GGP and GGP will also assume US$1,000,000 settlement liability on the outstanding Alegre purchase. Conditions The settlement of the proposed sale is subject to GGP completing its technical due diligence within 14 days of execution of the acquisition agreement.

All necessary shareholder and regulatory approvals and AKW obtaining the necessary approvals to distribute the GGP shares in specie to its shareholders upon issue. The Company, on completion of this transaction, continues to consider other investment opportunities which will deliver the required shareholder returns. ANDREW WALLER Director

Market update Sales growth returns in H2 AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively, today announced unaudited preliminary results for FY2010.

FY2010 sales were $9.2 million, representing a decline of 18%, and 4% on a constant currency basis. The first half of FY2010 was characterised by constrained research and healthcare spending and weak pharmaceutical contracting which affected the company’s sales. Some orders were deferred, with sales expected in FY2010 now anticipated in FY2011.

However, sales in H2 grew 4% on a constant currency basis and progress continued to be made throughout the year on a number of initiatives to position AtCor for the future. Sales in the US increased by 5% assisted by the return of pharmaceutical sector contracting activity in the second half. Clinical sales to medical specialists such as cardiologists, hypertension specialists and nephrologists continued to grow, rising 43%. Sales in Europe declined 29%, reflecting the impact of reduced funding for the largely government-supported research and clinical sectors.

Sales in Asia Pacific declined 8%. Gross margin improved by over 500 basis points from 84.5% in 2009 to 90.1%, reflecting the lower production costs from a full year of the SphygmoCor EM3 system released in November, 2008 and sales of previously leased pharmaceutical systems. Preliminary FY2010 net loss is expected to be between $1.1 million and $1.3 million, compared to ($1.7 million) in FY2009. Cash at 30 June 2010 was $1.6 million, down $1.8 million compared to 30 June 2009. Net operating outflows for the year were ($2.6 million), though net outflows were less than $0.4 million in H2, reflecting improved collections and tight expense management. Duncan Ross, CEO of AtCor Medical said “This was a year in which the global financial crisis impacted our markets, and uncertainty about US Healthcare reform effectively shut down new pharmaceutical contracts until legislation was signed in March.

Despite this, growth returned in the second half and important milestones were achieved, including the two positive Medicare reimbursement decisions in Michigan. While healthcare and research budgets remain tight and economic recovery has been slow, we expect sales to return to double digit levels on a constant currency basis in FY2011. We continue to invest in new product development to support our market leadership and future, and have a solid pipeline of sales opportunities to build from.” About AtCor Medical AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease.

Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects that cannot be detected with standard blood pressure monitoring. Central blood pressure has been found to be a superior predictor of cardiovascular events such as stroke, heart attack and kidney disease. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical and research institutions and in clinical trials with leading pharmaceutical companies.

The company’s technology has been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in the United States, Australia, and Europe. For further information, please visit our web site at www.atcormedical.com. For further information, please contact: Duncan Ross – AtCor Medical CEO +1 (630) 228 8873 Peter Manley – AtCor Medical CFO +61 (2) 9874 8761 Media enquiries to: Ashley Rambukwella – Financial & Corporate Relations Ph: +61 (2) 8264 1004/ m.

0407 231 282 or a.rambukwella@fcr.com.au.

BPH Corporate Limited (BPH) is pleased to announce that Principal Researcher Dr Robin Scaife has been awarded funding from the Scott Kirkbride Melanoma Research Centre (SKMRC) to spearhead a melanoma drug discovery programme at the Western Australian Institute for Medical Research (WAIMR).

The one year discovery grant was presented to Dr Scaife at the annual SKMRC fundraising luncheon. The SKMRC supports research that is aimed at providing crucial breakthroughs for improved diagnosis and treatment of melanomas and was established in 2005 in memory of Perth golfer, Scott Kirkbride, who lost his battle with this disease in 2004 at the age of 27.

Although melanomas have a reputation for being particularly refractory to therapeutic intervention, some types of melanoma have recently been shown to respond well to a new class of customized cancer drugs. Dr Scaife and his collaborators at WAIMR and the University of Western Australia, will use the high-content imaging and analysis platform at Molecular Discovery Systems to screen an arsenal of new drug-like molecules for inhibitors of melanoma cell survival and proliferation.

For more information contact: Mr David Breeze BPH Corporate Limited Tel : +61 8 9328 8366.

SomnoMed finishes the year with record quarter 26th July 2010, Sydney:

SomnoMed Limited (SOM) SomnoMed recorded the period of the highest unit sales and revenues in the final quarter of the 2009/10 fiscal year, with sales of 5,531 units generating revenues of $3.16 million (unaudited) for the three months to the end of June. This has brought the total number of units sold during the 2009/10 year to 19,543, representing an increase of 59.5% over the 12,254 units sold in the 2008/09 year. Revenue grew by 42.4% compared to the same quarter in the previous year, affected by a stronger Australian Dollar. Volume growth in this year’s June quarter was up by 51%, compared to the previous year.

North American sales represented 66.5% of global unit sales. Europe is the fastest growing region, selling 1,109 units in the three months to the end of June, up by over 100% compared to the same period in the previous year and now, for the first time, exceeding 20% of total global sales. Asia- Pacific represented 13.5% of global sales, dominated by revenues generated in Australia, whilst Japan and South East Asia are developing slowly in line with their local treatment protocol, still dominated by surgery or being held back by reimbursement issues. Ralf Barschow, SomnoMed’s CEO, said, “ We are very pleased with the result in the last quarter, which allowed us to finish the year close to 20,000 units, well up from our original target for the 2009/10 year.

Europe shows excellent growth prospects in a number of countries now recommending oral appliance treatment as first line treatment for sleep disordered breathing and offering partial or full reimbursement to patients.” “Our growth in the North American market was 51% higher than in the same quarter last year. This brings the total number of units sold in 2009/10 in the US and Canada to over 13,300, compared to 8,000 in the previous year. Based on our research, we believe SomnoMed has become the market leader in quality, custom made oral appliances in the US dental market, with a likely share of 25 – 30%.” “There are now a number of very important strategic initiatives underway in our most important market, which we believe will develop and strengthen SomnoMed’s position in the medical market and position our SomnoDent® device as the principal, more patient friendly and therefore more compliant treatment alternative for sleep disordered breathing conditions, ” said Mr. Barschow.

SomnoMed generated a total of $869,000 in net operating cash during the June quarter and received a further $436,000 from the issue of shares, as a result of conversion of options. This allowed SomnoMed to finish the year with a cash position of $4.3 million, compared to $3.1 million at the end of the previous quarter. “The good operating cash flow in the June quarter allowed us to finish the year with $4.3 million in the bank, up by almost $300,000 compared to end of June 2009. This is an excellent result, bearing in mind that we invested over $570,000 during the year in building and expanding our production capacity,” said Mr. Barschow.

For more information contact: Mr. Ralf Barschow, CEO, SomnoMed Limited +61 2 9467 0420

How the SomnoDent® MAS works The medical term for your lower jaw is ‘mandible’ and an oral appliance worn over the teeth is a ‘splint’, hence the name SomnoDent® Mandibular Advancement Splint, or SomnoDent®MAS. The SomnoDent®MAS consists of two acrylic plates fitted over the upper and low teeth. A patented fin coupling mechanism on the lower arch accurately positions the lower jaw (mandible) a little forward of its natural position. This positioning tightens the soft tissue at the back of the throat to stop it from collapsing – the cause of snoring (partial collapse) and sleep apnoea (full collapse).

SomnoDent® MAS allows the normal opening and closing of the mouth, allowing the user to yawn, speak and drink. The device will last 5 years and comes with a warranty. The SomnoDent® MAS is provided to patients through an integrated clinical protocol, involving dentists, primary care practitioners and sleep physicians. This pathway ensures that all patients are appropriately diagnosed and that only suitable patients are fitted with the device.

On behalf of the Board of Directors, I am pleased to advise that Medivac Limited (“MDV” or “Company”) has introduced a share purchase plan (“Plan”).

The Plan will be on similar terms to the recent placement to sophisticated investors including entities associated with significant shareholders The Copulos Group, and Shayden Nominees, and Executive Chairman Paul McPherson. Pursuant to the Plan, MDV will offer to all eligible shareholders (see conditions below), irrespective of the size of their respective shareholding (“Offer”), the opportunity to subscribe for up to AUD$15,000 worth of new fully paid ordinary shares in the Company (“Plan Shares”). The Offer is open to all MDV shareholders who are registered as holders of shares in the Company at 7.00pm (EAST) on 14 July 2010 (“Record Date”) and whose address as recorded in the register is in Australia or New Zealand (each an “Eligible Member”).

The Company previously offered an SPP to eligible shareholders on 15 September 2009 which is within the 12 month period imposed by ASX Listing Rules 7.2 exception 15, and 10.12 exception 8. Accordingly, any eligible shareholder who participated in that SPP to the permitted maximum of $15,000, is not eligible to participate in this Offer announced on 15 July 2010. Shareholders who participated in the September 2009 SPP for an amount less than $15,000 are eligible to participate in this Offer for an amount equivalent to the difference.

For example, if an eligible shareholder participated in the September 2009 SPP for an amount of $10,000 then that shareholder may only participate in this Offer for an amount of up to $5,000. Full details of the Offer are set out in the attached Terms and Conditions and Application Form Purpose of the Plan.

The funds raised under the Plan will be used to:

a) Finalise development of a new-concept MetaMizer for domestic and export markets. The new MetaMizer will have increased capacity, extended longevity and reliability, and reduced maintenance requirements. Funds will be used to complete the development and building of the prototype and the necessary trials, testing, registration and documentation. The company is concurrently building a strong prospective pipeline of sales opportunities both overseas and in Australia.

b) Build inventory for the rollout of SunnyWipes Antimicrobial Gel range into the professional market, following the recently announced TGA approval, and for associated marketing support. the Company is currently seeking listing for its range in the key Public Hospital systems (e.g. Hospital Purchasing Victoria (HPV)).

c)Complete further work necessary for TGA approval of the Company's General Virucidal and Antimicrobial Workplace Wipes.

d)Undertake further product development with SunnyWipes to launch line extensions leveraging the Company's unique intellectual property and to support the above launch into the professional channels. The Offer allows Eligible Members to increase their holdings into a more meaningful and financially viable marketable parcel of shares without incurring any brokerage and associated charges.

It also offers Eligible Members the opportunity to support the growth of the Company by making a direct cash investment into MDV. The Company is excited with the opportunities being pursued across both its SunnyWipes and MetaMizer businesses and encourages Shareholders to participate at this time.

Important Information

The issue price of the Plan Shares will be 0.7 cents per Plan Share which was the price at which a placement to sophisticated investors was made on 8 July 2010.

The average share price for the 5 days prior to the Announcement Date was 0.8 cents and the offer price is 87.5% of that.

The Plan opens on 22 July 2010 and will close on 5 August 2010 ("Closing Date").

Under the Plan, each Eligible Member may subscribe for a parcel of Plan Shares valued at either AUD2,000, AUD5,000, AUD10,000 or AUD15,000, subject to the maximum amount limitation in any 12 month period imposed by the ASX Listing Rules.

No brokerage, commission, stamp duty or other transaction costs will be payable by any shareholders in respect of their application for, and issue of, Plan Shares.

The Plan is not underwritten. The closing price of MDV shares as at 15 July 2010 was 0.8 cents. Eligible Members should appreciate that the market price for the MDV shares may change between the date of the Offer, and the date when the Plan Shares are issued to applicants under the Plan, with the effect that the issue price may be more or less than the market price for those securities on the day of issue. Members should seek their own independent legal and/or financial advice prior to making an application for Plan Shares and should specifically consider the risk of movement in market value of MDV's shares between the date of Offer and date of issue. How to Apply for Plan Shares If you would like to participate in the Plan, please carefully read the attached Terms and Conditions, and return your completed Application Form, together with your cheque for the value of Plan Shares applied for.

Your Application Form must be received on or before 5.00pm (EAST) on the Closing Date. Directors' Participation With the exception of Directors S Copulos and PD McPherson, each of whom participated in the recent Special Placement, each MDV director intends to participate in the Plan. If you have any questions in relation to the above matter, please contact Mr Paul McPherson, Executive Chairman on 0411 428 734. Yours faithfully Paul McPherson Executive Chairman

The following sets out the terms and conditions for the Share Purchase Plan ("the Plan"). By returning the Application Form, you will have agreed to be bound by these Terms and Conditions and the Company’s Constitution. The Plan is being conducted in accordance with Class Order 09/425 issued by the Australian Securities and Investments Commission (“ASIC”) on 18 June 2009 as amended. Accordingly, the Company is exempted from the requirements contained in Parts 6D.2 and 6D.3 of the Corporations Act 2001 (Cth).

The Company is not required, and will not be issuing a prospectus in relation to the Plan. The Company will conduct the Plan so that it complies with ASX Listing Rules 7.1 and 10.11 to the extent necessary to permit MDV, without obtaining shareholder approval, to issue up to $15,000 worth of Plan Shares to each Eligible Shareholder, including related parties, who subscribe under the Plan. Accordingly, the Company will not be seeking the approval of shareholders in relation to the implementation of the Plan. 1.Key Dates This timetable is indicative only. The Company reserves the right to vary the details contained in this indicative timetable without notice. On 8 July 2010 the Company issued a cleansing notice in accordance with section 708A(6) of the Corporations Act.

In accordance with Class Order 09/425 issued by ASIC, the Company is not required to issue a further cleansing notice for the Plan. 2.Eligibility to participate

(a)Those members of the Company who will be eligible to apply for shares in the issued capital of the Company (each a “Plan Share”) under the Offer (each an “Eligible Member”) are those who: are recorded in the Company’s register of members at 7.00pm EAST on the record date of 14 July 2010 (“Record Date”); Did not participate to the maximum permitted amount of $15,000 in the Share Purchase Plan offered on 15 September 2009: and have an address (as recorded in the Company’s register of members ) in Australia or New Zealand.

(b)This Offer does not constitute an offer in any jurisdiction which, or to any person to whom, it would not be lawful, in the reasonable opinion of the Company, to make such an offer. Shareholders who hold MDV shares on behalf of persons who reside outside Australia or New Zealand ("Ineligible Persons") or who act for the account or benefit of Ineligible Persons are not entitled to participate in the Plan.

(c)Shareholders who are joint holders of shares are taken to be a single registered holder of MDV shares for the purposes of determining whether they are an Eligible Member.

(d)Where a trustee or nominee is a registered holder of MDV shares and is expressly noted on the share register as holding MDV shares on account of another person ("a Beneficiary"), the Beneficiary will be taken to be the registered holder of those MDV shares. In this instance, an application or issue of Plan Shares to the trustee or nominee will be taken to be an application or an issue to the Beneficiary.

(e)If you are an Eligible Member, your rights under this Offer are personal to you and are non-renounceable, which means you cannot transfer your rights to another person.

(f)Where a registered shareholder is a custodian, the custodian may subscribe for Plan Shares on behalf of eligible beneficial holders with a total application price exceeding $15,000 only if they complete and return the attached custodian certificate with their application.

3.Offer Price (a)The issue price of the Plan Shares will be 0.7 cents per Plan Share, which is the same price at which a placement to sophisticated investors was made on 8 July 2010. The average price over the 5 days prior to the Announcement date was 0.8 cents; and

(b)The closing price of MDV shares as at 15 July 2010 was 0.8 cents. Eligible Members should appreciate that the market price for the MDV shares may change between the date of the Offer, and the date when the Plan Shares are issued to applicants under the Plan, with the effect that the issue price may be more or less than the market price for those securities on the day of issue. Shareholders should seek their own independent legal and/or financial advice prior to making an application for Plan Shares and should specifically consider the risk of movement in market value of MDV's shares between the date of Offer and date of issue.

4.Applying for Plan Shares (a)Participation in the Plan is optional. Eligible Members may apply to purchase a parcel of Plan Shares with a value of either AUD2,000, AUD5,000, AUD10,000 or AUD15,000. Under ASX Listing Rules 7.2 Exception 15 and 10.12 Exception 8, the number of shares issued under a share purchase plan must not be greater than 30% of the number of fully paid shares already on issue. In this case the applicable date for the 30% calculation is 8 September 2009. The Company reserves absolute discretion to scale back applications under the Plan to a level that it considers reasonable for its requirements, having regard to the 30% maximum.

(b) Eligible Members wishing to participate in the Plan, must follow the instructions on the Application Form and complete the Application Form and provide a cheque or money order to the Company (at the address set out in the Application Form), so that it is received by the share registry by 5.00 pm (EAST) on 5 August 2010 ("the Closing Date").

(c)Eligible Members who apply for Plan Shares under the Plan will apply for a certain value, rather than a certain number, of Plan Shares. The Company will divide the parcel value selected by the Issue Price (as determined under clause 3(a)) in order to determine the number of Plan Shares applied for (rounded up or down to the nearest whole number).

(d)Eligible Members who receive more than one Offer under the Plan (for example, because they hold MDV shares in more than one capacity) may apply on different Application Forms for Plan Shares but may not apply for Plan Shares with an aggregate value of more than AUD15,000.

(e)MDV may accept or reject applications for Plan Shares at its discretion. For instance, the Company may reject any application in the following circumstances (among others): (i)an Application Form is incorrectly completed, incomplete or otherwise determined by MDV to be invalid; (ii)an Application Form is not received by the Closing Date. (iii)an application is for less than AUD2,000 worth of Plan Shares; (iv)the cheque accompanying an Application Form is dishonoured or is not made out for the amount corresponding to the amount of Plan Shares applied for; (v)it appears that an applicant is applying to buy more than an aggregate of AUD15,000 of Plan Shares; (vi)MDV believes an applicant is not an Eligible Member (subject to compliance with any applicable Australian Securities and Investments Commission or ASX requirements). (vii)MDV believes that acceptance of the application or issue of the Plan Shares may be contrary to any applicable law or regulation.

(f)MDV reserves the right to complete or amend any Application Form received if such amendment would assist or permit the Company and or the shareholder to issue/receive shares under the Plan. Furthermore, the Company reserves the right to issue fewer Plan Shares than an Eligible Member applied for under the Plan (or none at all) if it believes that the allotment of those Plan Shares would contravene any law or the Listing Rules of the ASX.

(g)In accordance with ASX Listing Rule 7.2 Exception 15, no more than 30% of MDV's issued ordinary shares as at 8 September 2009 may be issued under the Plan without receiving shareholder approval. The Company does not propose seeking shareholder approval for the Plan and accordingly, does not intend issuing more than 30% of MDV's issued ordinary shares as at 8 September 2009 under the Plan. If the issue price calculated in accordance with clause 3(a) would result in the number of Plan Shares subscribed for being more than 30% of MDV’s issued ordinary shares as at 8 September 2009 then MDV may, at its discretion, undertake a scaleback of the Offer to the extent and in the manner it sees fit. If there is a scaleback applicants may receive fewer than the parcel of Plan Shares for which they applied.

(h)If for whatever reason an applicant receives fewer than the parcel of Plan Shares for which they applied then the Company will refund without interest the difference between the value of the Plan Shares allotted and the number of Plan Shares applied for.

5.Issue of Plan Shares

(a)Plan Shares issued under the Plan shall rank equally with, and have the same terms as the Company’s other listed fully paid ordinary shares. Application will be made to ASX for quotation of the Plan Shares.

(b)It is intended that the Plan Shares will be allotted within 10 business days of the Closing Date. Shareholders will be issued with a holding statement or confirmation shortly after the allotment of the Plan Shares.

(c)Any proposed date in these Terms and Conditions relating to quotation and trading of the Plan Shares is indicative only. Any person who trades any shares before receiving a holding statement does so at their own risk.

(d)Because of the limitation imposed on certain of the eligible shareholders who participated on the September 2009 Plan, and the ASX Listing Rule that limits the maximum issue to 30% of the issued capital as at 8 September 2009, it is not possible for this Offer to be fully subscribed at AUD15,000. The maximum possible issue as a result of this Offer is 28,038,486 ORD shares which would raise from existing Shareholders approximately AUD196,269.

If the total applications received is in excess of this number, then all applications will be scaled back. The Plan will not be underwritten.

6.Conditions of Application

(a)Shareholders who apply to participate in the Plan by completing and returning the Application Form: (i)represent that they are an Eligible Member; (ii)confirm that they have not applied for more than AUD15,000 of Plan Shares under the Plan, including participation in the September 2009 SPP, even though they may have received more than one offer under the Plan or received offers in more than one capacity under the Plan; (iii)agree that their application is made on the Terms and Conditions of the Plan set out in these Terms and Conditions and the Application Form; (iv)accept that they will not be able to withdraw or revoke their application once they have sent it in; (v)authorise MDV (and its officers or agents) to correct any error or omission in their Application Form and to complete the Application Form by the insertion of any missing details; (vi)acknowledge that MDV may at any time determine that their Application Form is valid, in accordance with the Terms and Conditions, even if the Application Form is incomplete, contains errors or is otherwise defective; (vii)acknowledge that the Plan Shares have not, and will not be, registered under the securities laws of any state or jurisdiction outside of Australia or New Zealand; (viii)are responsible for any dishonour fees or other costs MDV may incur in presenting a cheque for payment which is dishonoured; (ix)acknowledge that neither MDV nor Link Market Services Limited has provided any investment advice or financial product advice, and that neither has any obligation to provide this advice, concerning any decision to apply for and buy Plan Shares; (x)acknowledge that MDV is not liable for any exercise of its discretions referred to in these Terms and Conditions; and (xi)irrevocably and unconditionally agree to the Terms and Conditions and agree not to do any act or thing which would be contrary to the spirit, intention or purpose of the Plan.

7.Costs of Participation MDV will not charge any brokerage, commissions or other transaction costs in respect of the application for and allotment of Plan Shares under the Plan.

8.Taxation MDV makes no representations or warranties in respect of, and accepts no responsibility for, the liability of Eligible Members to pay income tax in respect of any issue of Plan Shares, payment of other transaction pursuant to this Plan.

9.General (a)The Company’s rights pursuant to the Plan may be exercised by the directors of the Company or any delegate of the directors who will have absolute discretion to: (i)determine appropriate procedures for the administration of the Plan consistent with these Terms and Conditions; (ii)resolve conclusively all questions of fact or interpretation arising in connection with the Plan or these Terms and Conditions; and (iii)delegate to any one or more persons, for such period and on such conditions as they may determine, the exercise of their powers or discretions under the Plan or these Terms and Conditions. (b) The Plan and these Terms and Conditions may be suspended, terminated or amended at any time by the Board. In particular the Board may waive compliance with any provision of these Terms and Conditions, or vary these Terms and Conditions if required to comply with the Listing Rules of the ASX.

In the event of termination of the Plan, all monies received from shareholders in respect of applications shall be refunded without interest. (c)MDV may settle in any manner it thinks fit any disputes which may arise in connection with or by reason of the operation of the Plan and the decision of MDV will be conclusive and binding on all participants and other persons to whom the determination relates. (d)These Terms and Conditions are governed by the laws of New South Wales.

Orthopaedic implant manufacturer, Austofix (AYX) has appointed three more overseas distributors – in the UK and Ireland, the Czech Republic and Slovakia – as it pursues export growth. This brings to twelve the total number of overseas distributors, with ten appointed in the past year.

The UK/Ireland appointment has resulted in an immediate pay‐off with Austofix receiving an order from Lavender Medical for a number of products to fix and stabilise fractures – Volar Radius Plates (VRP) for wrist fractures and Tectona Plates for hip fractures. Austofix CEO, Mark Szolga, said: “Our export strategy is beginning to pay off as a result of our ability to respond quickly, to offer innovative products and to price them competitively. Although small in number, we’ve already had repeat orders from Spain, South Africa and Turkey.

We have particularly high hopes for our products’ acceptance in Spain following our official launch event in Madrid, which attracted 40 orthopaedic surgeons.” Austofix is now well represented in a number of western and eastern European countries, in the middle‐east and in South America.

“We believe that appointing distributors is absolutely the right way to go outside Australia. Effective distributors offer an immediate sales and distribution network and we minimise risk. Moreover, our broad export focus maximises the potential for a continuous flow of orders – so much so that we expect export orders will account for a significant part of revenue this financial year.” Mr Szolga said distributors had indicated they appreciate the company’s responsiveness, flexibility, support and adherence to a ‘gold standard’ of product.

“We try to respond to orders or a request within a very short timeframe, days if possible. This enables our distributors to follow up on opportunities quickly. Austofix has installed a second five‐axis milling machine at its manufacturing plant in Adelaide. As a result of the expansion of distribution channels, the company is building capacity to ramp up production in the next few months. Additionally, following Commonwealth Government approval in April, Austofix expects to begin marketing and sales for its hip replacement products in September.

The company believes the products’ high quality and competitive pricing will result in growing demand by a health sector struggling under considerable cost pressures. Further information Mark Szolga CEO, Austofix Group Limited 08 8351 0644 www.austofix.com.au

Distributors appointed so far to: Argentina, Greece, Turkey, Brazil, South Africa, Romania, Spain, the middle‐east, the UK/Northern Ireland, China/Malaysia, the Czech Republic and Slovakia. NB: Distributors in both Argentina and in China/Malaysia have been in place for more than a year.

Healthscope Board unanimously recommends cash offer of $6.26 per share from The Carlyle Group and TPG Capital

Healthscope announces today that it has entered into a Scheme Implementation Agreement (“SIA”) with funds advised by The Carlyle Group and TPG Capital (the “Consortium”) under which it is proposed the Consortium will acquire all of the ordinary shares in Healthscope under a Scheme of Arrangement (“Scheme”). Under the terms of the Scheme, Healthscope shareholders will receive $6.26 in cash per share, valuing Healthscope at approximately $2.7 billion. The price will be reduced by any future dividends that Healthscope pays to shareholders prior to completion.

The Board of Healthscope unanimously recommends that Healthscope shareholders vote in favour of the Scheme at the Scheme meeting, in the absence of a superior proposal and subject to an independent expert concluding that the Scheme is in the best interests of Healthscope shareholders.

The price of $6.26 per share represents:

• A premium of 39% to the closing price of $4.50 on 13 May 2010, the day prior to the announcement that Healthscope had received an indicative proposal;

• A premium of 43% to the three month volume weighted average price prior to 13 May 2010 of $4.36;

• A premium of 46% to the closing price on 13 May 2010 adjusted for movements in the S&P/ASX 200 between 13 May 2010 and 16 July 2010 of $4.28;

• A premium of 51% to the three month volume weighted average price prior to 13 May 2010 adjusted for movements in the S&P/ASX 200 between 13 May 2010 and 16 July 2010 of $4.15.

As previously announced on 31 May 2010, following receipt of a number of indicative and non-binding proposals the Board determined that it was in the interests of shareholders that a formal process be conducted to evaluate whether a change of control offer, at a price and on terms that the Board would recommend, could be secured. A comprehensive process was established including access to due diligence materials for a number of interested parties to enable them to make binding proposals. Following the receipt of proposals from parties after market close on 16 July 2010, the Board has concluded that the Consortium’s proposal provides the best outcome for Healthscope shareholders, both in terms of value and associated terms and conditions.

The Board unanimously recommends the Scheme in the absence of a superior proposal and subject to an independent expert concluding that the Scheme is in the best interests of Healthscope shareholders. Subject to those same qualifications, each Director of Healthscope intends to vote all the Healthscope shares held or controlled by them in favour of the Scheme at the Scheme meeting. The transaction is subject to certain conditions precedent including Healthscope shareholder and court approval of the Scheme and other regulatory approvals. A copy of the executed SIA entered into by Healthscope and the Consortium is attached to this announcement, which includes the conditions precedent for the Scheme and exclusivity provisions, including providing for the payment of a break fee to the Consortium and a reverse break fee to Healthscope in certain circumstances.

Importantly for Healthscope, under the SIA the Consortium has provided substantial financing certainty and there is limited conditionality for a transaction of this nature. A Scheme booklet containing information relating to the proposed acquisition, reasons for the Directors’ unanimous recommendation, and details of the Scheme meeting is expected to be sent to Healthscope shareholders in September with a shareholder meeting to vote on the proposed Scheme to be held in early October. Subject to the approval of the Scheme by shareholders and the court and the timely satisfaction (or waiver) of conditions, Healthscope expects the transaction to be completed by October. Linda Nicholls, Healthscope Chairman, said: “Following the receipt of a number of approaches in May, the Board determined that it was in shareholders’ best interests that a formal process was undertaken to thoroughly evaluate whether a change of control offer, at a price and on terms that the Board would recommend, could be secured. This process has maximized shareholder value through encouraging competitive tension. “After careful consideration the Board has unanimously concluded that the Consortium’s offer provides shareholders with an excellent opportunity to realise considerable value from their investment in Healthscope.

Whilst the Board is of the strong belief that the Company is well positioned to continue to deliver strong growth for shareholders into the future, the Board determined that the relative certainty delivered by this cash offer at a substantial premium was in the best interests of Healthscope shareholders.” The Consortium comprises two of the world’s leading private equity firms, collectively managing over US$135 billion in equity capital. In addition, the members of the Consortium have a longstanding track record of investing in and growing businesses within the healthcare sector both in Asia and globally. We have been informed that that Consortium intends to retain management and support management’s strategy, business plans and growth initiatives for all parts of the business. Healthscope is being advised by Goldman Sachs JBWere, Lazard and Minter Ellison.

For further information please contact: Healthscope Investor Relations: Caroline Sladen (03) 9926 7848 0419 526 355 Media Communications: nightingale communications Kate Inverarity Lisa Keenan 0413 163 020 0409 150 771.

MEDIVAC LIMITED SHARE PURCHASE PLAN Medivac Limited (the “Company”) has established a new Share Purchase Plan (the “Plan”) and is offering each eligible (subject to conditions) shareholder the opportunity to purchase up to $15,000 of ordinary shares in the Company under the Plan. The Plan offer document will be forwarded to all eligible shareholders next week. The Plan will be on similar terms to the recent placement to sophisticated investors including entities associated with significant shareholders The Copulos Group and Shayden Nominees, and Executive Chairman Paul McPherson. The Plan allows every eligible shareholder to purchase up to $15,000 of ordinary shares in lots of $2,000, $5,000, $10,000 or $15,000. In order to comply with the ASX Listing Rules, any eligible shareholder who participated in the Company's September 2009 Share Purchase Plan ("SPP"), and who wishes to participate in this Plan, will have their eligible dollar amount reduced by the amount invested in the 2009 SPP.

Full details will be provided in the Plan offer document. The Plan is a cost-effective means both for existing investors to increase their holding in the Company and for the Company to raise additional funds to help ensure that it delivers on milestones and objectives. Record Date: The record date for the Plan is Wednesday 14 July 2010. Paul McPherson Executive Chairman

“MDV” MediVac delivers cleaner, safer healthcare solutions. MediVac Technology offers a best practice solution to the handling and remediation of clinical waste. The MetaMizer is an environmentally friendly alternative waste management system for hospitals and quarantine facilities, providing sterile, safe waste disposal on site and reducing waste to landfill by up to 90%. SunnyWipes are a range of powerful hard surface wipes and hand sanitising gels produced with ingredients derived from natural sources. Using green chemistry, SunnyWipes provides a more natural solution for infection control and disinfection on topical skin and non porous hard surfaces. SunnyWipes decrease human and environmental health risks. Media enquiries: Richard Allen Oxygen Financial Public Relations Ph: 03 9915 6341.

LCT reports consistent benefit in DIABECELL® NZ Trial

•8 patients in New Zealand have received DIABECELL® implants according to schedule

•All 4 patients given 10,000 islet equivalents/kg showed reduction in episodes of clinically significant hypoglycaemia (low blood glucose)

•Improved blood glucose control shown with reduction in insulin requirements

•Second group of 4 patients have received 15,000 IEQ/kg 

Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited ( LCT; OTCQX: LVCLY), a global company pioneering the development of cell implants to treat diabetes, today reported further positive results from the New Zealand Phase II clinical trial of DIABECELL® , with all eight insulin dependent diabetes patients having now received the implants of encapsulated porcine islets. In the first cohort of patients with unstable diabetes, all have shown the benefit of reduction or elimination of episodes of low blood glucose levels that are often life-threatening. The dramatic results to date showing DIABECELL®’s ability to ameliorate this serious complication of diabetes, known as hypoglycaemic unawareness, are a key indicator of benefit to patients.

The first four New Zealand patients received one implant of DIABECELL® at the dose of 10,000 islet equivalents per kilogram body weight (IEQ/kg) without remarkable adverse events attributable to the treatment. This continues to confirm DIABECELL®’s safety profile. Two patients have been followed up for 24 weeks and two patients for a minimum of 12 weeks. All patients have reduced the number or severity of hypoglycaemic events, which are episodes when blood glucose levels are low and may lead to loss of consciousness and convulsions without warning symptoms. By 12 weeks, the severity score of hypoglycaemic episodes in these 4 patients was reduced by a mean of 67% (score of 83 reduced to 28) and the number of hypoglycaemic episodes was reduced by 44% (30 episodes reduced to 17). In three patients with hypoglycaemic unawareness, the number of such episodes was reduced by 90% from 19 events down to just 2. A highlight has been the patients that were followed up for 24 weeks: one patient experienced only one further episode of hypoglycaemic unawareness while the other patient had no further attacks. In the first 4 patients receiving the 10,000 IEQ/kg DIABECELL® treatment, the insulin dose reduction ranged from 6% to 25% at 12 – 24 weeks.

Daily insulin dose is adjusted according to daily blood glucose measurements by the patient. Blood glucose control as reflected by HbA1c and 72-hour continuous glucose monitoring showed improvement. Details of HbA1c and continuous blood glucose monitoring are blinded to the clinical team who serve as independent trial officiators. This information relating to response of blood glucose control to treatment will be unblinded after one year follow-up. These results meet LCT’s expectations for this lower dose and are consistent with previous data generated at this dose. A second group of 4 patients has received a higher dose of 15,000 IEQ/kg with no significant adverse events attributed to the treatment. At this time, the follow up period is too short to assess response to treatment. Prof Bob Elliott, LCT Medical Director said: “It is satisfying to see that DIABECELL® has changed the lives of implant recipients and their families, even at this stage of our clinical trial. Hypoglycaemic unawareness occurs in about 20% of long standing insulin dependent diabetic people and is responsible for up to 8% of deaths in this group.” “Human islet transplants have attained similar relief from this life threatening complication, but of course this treatment is available to only a handful of people because of lack of donor tissue and, unlike our technology, involves lifelong dangerous immune suppressing drugs.” Dr Paul Tan, Chief Executive Officer LCT added: “We expect the dose ranging studies to continue delivering positive results. With consistent benefit in the reduction or elimination of hypoglycaemic events, LCT is planning to expand clinical trials of DIABECELL® to obtain the necessary pivotal data for the treatment to be approved.” New Zealand trial interim results are due in October 2010 and final unblinded results after one year follow up. DIABECELL® is LCT’s treatment designed to normalise the lives of people with insulin dependent diabetes. DIABECELL® comprises encapsulated porcine insulin-producing cells (islets) that are implanted into the abdomen of patients using a simple laparoscopic procedure, and work by self-regulating and efficiently secreting insulin in the patient’s body. LCT's breakthrough proprietary encapsulation technology means that patients receiving DIABECELL® treatment do not require immunosuppression after implantation. 

 For further information: www.lctglobal.com At the company: Dr Paul Tan Chief Executive Officer Tel:+64 9 276 2690 ptan@lctglobal.com Prof Bob Elliott Medical Director Tel:+64 9 276 2690 belliott@lctglobal.com Ms Susanne Clay Chief Business Officer Tel: +64 9 270 7954 sclay@lctglobal.com Media and investor enquiries: NZ and Australia: Buchan Consulting Rebecca Wilson Tel: +61 3 9866 4722 Mob: +61 417 382 391 rwilson@bcg.com.au Paul Dekkers Tel: +61 2 9237 2800 pdekkers@bcg.com.au About Living Cell Technologies – www.lctglobal.com Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson’s disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT’s technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

Nanosonics Limited (NAN) this morning said it has re-commenced production and shipment of its upgraded Trophon EPR devices, used for disinfecting ultrasound devices, following successful trials of the product. The company also said that its application for approval by the FDA was “firmly on track”.

Currently Nanosonics said it was finalising specifications and validation of a chemical indicator to meet US regulatory standards.

”Pending completion of this work and FDA approval, the Company remains on track for an initial product launch into the US market during 2011,” the company said.

Meanwhile in Australia, Nanosonics was upping production at its Alexandria, NSW premises and it currently held orders for over three months of production capacity.

At 1057 AEST, Nanosonics shares were trading up 1.5c to 54c.